Recent News
ORPHAGEN PHARMACEUTICALS AWARDED SBIR PHASE II GRANT TO DEVELOP A FIRST-IN-CLASS DRUG FOR ADRENOCORTICAL CANCER
Orphagen Pharmaceuticals, a privately-held pharmaceutical company, announced today that the National Cancer Institute (NCI) has indicated its intention to award the company $2.0 million under the Small Business Innovation Research (SBIR) program to support preclinical...
Orphagen Pharmaceuticals Announces Promotion of Paul Crowe to Vice President, Drug Discovery
Orphagen Pharmaceuticals, a preclinical stage biopharmaceutical company focused on discovering and developing first-in-class therapeutics for cancer and inflammatory disease, announced the promotion of Paul Crowe to Vice President, Drug Discovery, effective June 30,...
ORPHAGEN PHARMACEUTICALS TO PRESENT PRECLINICAL DATA FOR OR-449 AT THE ENDOCRINE SOCIETY’S 2021 ANNUAL MEETING
Orphagen Pharmaceuticals, an early-stage biopharmaceutical company focused on developing and commercializing novel therapies for cancer and other serious diseases with significant unmet need, today announced that data from its preclinical program to develop OR-449 for...
ORPHAGEN PHARMACEUTICALS AWARDED SBIR PHASE II GRANT TO INVESTIGATE RETINOIC ACID ANTAGONISTS AS MALE CONTRACEPTIVES
Orphagen Pharmaceuticals, a privately-held pharmaceutical company, announced today that the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) has awarded the company $1.8 million under the Small Business Innovation Research (SBIR)...
Orphagen Pharmaceuticals and the Pharmaceutical Division of Japan Tobacco Enter into a Collaborative Agreement
San Diego, June 1, 2018 – Orphagen Pharmaceuticals, a privately held pharmaceutical company, announced today that it has entered into a collaborative agreement with the pharmaceutical division of Japan Tobacco Inc. (JT) to discover, develop and commercialize drugs...